title: Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.
authors.affiliation: Department of Hematology, National Hospital Organization Osaka Minami Medical Center, 2-1, Kido-higashi, Kawachinagano, Osaka, 586-8521, Japan.
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Ohyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Kumode
authors.forename: Go
authors.initials: G
authors.lastname: Eguchi
authors.forename: Terufumi
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Maeda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018792:Encephalitis, Viral / Q000188:drug therapy / Q000209:etiology; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology*; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D054398:Receptors, CCR4 / Q000037:antagonists & inhibitors* / Q000276:immunology; D012074:Remission Induction; D013262:Stevens-Johnson Syndrome / Q000175:diagnosis / Q000209:etiology; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; C515354:CCR4 protein, human; D007166:Immunosuppressive Agents; D009363:Neoplasm Proteins; D054398:Receptors, CCR4; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D015774:Ganciclovir; C549035:mogamulizumab